Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportPoster - PhysicianPharm

MIRDcell v3.01 Predicts Response of Nonuniform Distribution of Ac-225 labeled Nanocarriers in Multicellular Tumor Spheroids

Sumudu Katugampola, Jianchao Wang, Aprameya Prasad, Stavroula Sofou and Roger Howell
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1576;
Sumudu Katugampola
1Radiology Rutgers New Jersey Medical School Newark NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianchao Wang
1Radiology Rutgers New Jersey Medical School Newark NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aprameya Prasad
2Johns Hopkins University Baltimore MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stavroula Sofou
2Johns Hopkins University Baltimore MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger Howell
3Rutgers New Jersey Medical School Newark NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

1576

Introduction: The MIRD Schema can be used to calculate the absorbed dose to tissues from radiopharmaceuticals. MIRDcell v2.17, software released by the MIRD Committee in 2014, implements the Schema to calculate absorbed doses and surviving fractions of cells in multicellular clusters that are labeled with radiopharmaceuticals. The accuracy of the biologic responses predicted with MIRDcell hinges in part on the distribution of cellular activity and corresponding distribution of cellular absorbed dose. In this work, we use experimentally measured activity distributions and a new version (v3.01) of MIRDcell to predict response of ~ 400 micro-meter diameter tumor spheroids to Ac-225 labeled liposome nanocarriers. Predictions are compared with experimental outcomes. Materials and Methods: The experimental data for the spheroids analyzed in this study was provided by the Sofou lab (published and unpublished). The liposomes were prepared with a releasing (R+) and a nonreleasing (R−) membrane, and an adhesion (A+) or no adhesion property (A-) to increase the exposure times of the tumor cells to the delivered therapeutics. Spheroids were treated with 0 or 9.25 kBq/mL of 225Ac-labeled nanocarrriers with the properties: R−A−, R−A+,R+A−, and R+A+. Following the end time at day 20, spheroids were plated for growth. Once the untreated condition reached confluency, the percent outgrowth was calculated as the number of cells counted for each treatment normalized by the number of cells of the untreated condition. The concentration of the nanocarriers as a function of radial position was measured at several times during the uptake and clearance phases. The time-integrated activity per cell was determined as a function of radial position and was estimated using a weighted fit, non-weighted fit and a hybrid of a trapezoidal and an exponential fit to the clearance data beyond the last data point, to uptake and clearance data. This time integrated activity per cell as a function of radial position was used as input data by MIRDcell v3.01, along with the estimated mean activity per cell, and the absorbed dose was calculated for each cell. The surviving fraction of cells in the spheroid was then simulated by MIRDcell for each nanocarrier.

Results: The uptake and clearance of the nanocarriers were best represented by the hybrid fit. Preliminary results of the MIRDcell-predicted surviving fraction for the drugs R+A+ and R−A− are in good agreement with the experimental fractional outgrowths. The results for R-A+ are within reason, however those for R+A- are in poor agreement.

Conclusions: This preliminary work demonstrated the ability of the software tool MIRDcell to predict the outgrowth of tumor cell clusters treated with Ac-225 nanocarriers with satisfactory accuracy in most cases. Further work is needed to improve the predictive accuracy. Acknowledgements: We acknowledge the contribution from all group members of the Sofou lab. This work was supported by the NIH grant number 1R01CA198073 and 1R01CA245139.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
MIRDcell v3.01 Predicts Response of Nonuniform Distribution of Ac-225 labeled Nanocarriers in Multicellular Tumor Spheroids
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
MIRDcell v3.01 Predicts Response of Nonuniform Distribution of Ac-225 labeled Nanocarriers in Multicellular Tumor Spheroids
Sumudu Katugampola, Jianchao Wang, Aprameya Prasad, Stavroula Sofou, Roger Howell
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1576;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
MIRDcell v3.01 Predicts Response of Nonuniform Distribution of Ac-225 labeled Nanocarriers in Multicellular Tumor Spheroids
Sumudu Katugampola, Jianchao Wang, Aprameya Prasad, Stavroula Sofou, Roger Howell
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1576;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Poster - PhysicianPharm

  • Preliminary result of Texture Analysis on prediction of overall outcome of neuroendocrine tumors based on pre-therapy heterogeneity of somatostatin receptors on 68Ga Dotatate PET/CT scans.
  • The Incremental Value of 18F FDG Labelled Leukocytes PET/CT Over 18F FDG PET/CT Scan in the Detection of Occult Infection
  • Respiratory motion correction reduces differences between immediate and delayed SPECT myocardial perfusion images
Show more Poster - PhysicianPharm

Dosimetry

  • Generation of clinical 177Lu SPECT/CT images for dosimetry in Molecular Radiotherapy based on Monte Carlo simulation with GATE
  • Radiation exposure to family caregivers of patients administered radioisotopes for nuclear medicine procedures
Show more Dosimetry

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire